This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 39 entries already.
Non-profit foundation BioInnovation Institute (BII) has unveiled its latest commitment to driving innovation and growth within the life science sector. Six promising companies will receive crucial financial support through BIIs […]
Dutch gene therapy company UniQure has launched a US$200m stock offering on Nasdaq.
Polpharma Biologics SA has partnered up with Novartis subsidiary Sandoz AG to market a natalizumab biosimilar. As part of the global commercialization agreement, Polpharma Biologics will be responsible for the […]
The FDA has given the go-ahead to PharmaMars proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung cancer.
Together with the EIB, five of the EUs largest national promotional banks and institutions plan to invest 10bn to accelerate the transition to a sustainable and circular economy.
Danish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.
Dutch biopharma company AM-Pharma B.V. has secured 116m to bring its acute kidney injury treatment into Phase III.
Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos pipeline and drug discovery platform.
German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
French microalgae specialist Microphyt has raised 28.5m to develop its microalgae portfolio for nutrition and cosmetics.